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Introduction: Endurance sports have recently been recognized as a risk factor for atrial ﬁbrillation (AF).
This study aimed to characterize AF in endurance athletes and to examine the efﬁcacy of pulmonary
vein antrum isolation (PVAI) in an attempt to clarify the mechanism.
Methods and results: Twenty-two men (4678 years old) with AF, who had no risk factors other than
participation in long-term endurance sports, were examined; 12 patients had paroxysmal AF, 9 had
persistent AF, and 1 had long-standing AF. Twelve patients (55%) were asymptomatic at rest. Nineteen
patients (86%) experienced less exercise tolerance during AF than during sinus rhythm; exercise-
induced paroxysmal AF was noted in 14 of these patients (64%). Antiarrhythmic drugs (AADs) were
used in 18 patients, but were effective in only 3 patients (16%). Eleven patients underwent PVAI; in
these patients, AF was eliminated without AADs in 9 patients (82%) and with AADs in 2 patients over an
average follow-up period of 2179 months.
Conclusion: AF in endurance athletes is frequently asymptomatic at rest, but manifests as reduced
exercise tolerance. AF originates from the pulmonary veins; PVAI could be an effective non-pharmaco-
logic therapy.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Long-term endurance sports have recently been recognized as
one of the risk factors for atrial ﬁbrillation (AF) [1–8]; widely
accepted risk factors for AF include age, hypertension, diabetes
mellitus, structural heart disease, hyperthyroidism, obesity, and
heavy alcohol intake [9–12], although moderate physical activity
may decrease the risk of AF [13]. Elosua et al. [4] reported that a
lifetime of sport activities of at least 1500 h is associated with a
higher risk of AF, and there are increasing data that AF is 2–10
times more prevalent in active or former athletes in Europe
and America [1–8]. A substantial number of endurance athletes
experience AF in Japan, which may be explained by the rise in
popularity of jogging among the Japanese, but the connection
remains unclear.
AF has been reported to originate in the pulmonary vein (PV)
in the majority of patients with paroxysmal AF and in a sub-
stantial number of patients with persistent AF [14,15]; PV antrumrt Rhythm Society. Published by E
: þ81 96 368 0414.
hiya).isolation (PVAI) eliminates AF in these patients [16,17]. However,
the mechanism underlying the relationship of AF with endurance
sports remains unclear, and there are limited data regarding the
efﬁcacy of PV isolation for AF [18,19]. Therefore, this study aimed
to characterize AF in endurance athletes and to examine the
efﬁcacy of PVAI in an attempt to clarify the mechanism.2. Methods
2.1. Patients
This study included 22 male athletes with AF (age, 4678 years;
range, 32–54 years). Athletes were deﬁned according to previously
described criteria [4] as individuals who had performed endurance
sports for more than 3 h per week for at least 10 years prior to the
arrhythmia diagnosis. All patients were dedicated to endurance
sports, including daily jogging, swimming, and skiing; 12 patients
(55%) had completed full marathons.
In all patients, transthoracic echocardiography and/or cardiac
magnetic resonance imaging (MRI) were performed to exclude
underlying structural heart diseases, measure cardiac chamberlsevier B.V. All rights reserved.
Table 1
Characteristics of Study Patients.
Patient number N¼22
Age (years, range) 4678 (32–54)
Male gender 22 (100%)
Type of AF
Paroxysmal 12 (55%)
Persistent 9 (41%)
Long-standing 1 (5%)
History of AF (years) 4.273.0
LAD (mm) 3976 (32–49)
LVEDD (mm) 5374
LVESD (mm) 3374
LVEF (%) 6777
BMI (kg/m2) 23.372.3
Sinus rate at rest (bpm) 5279
AF¼atrial ﬁbrillation; BMI¼body mass index; bpm¼beats per
minute; LAD¼anteroposterior left atrial diameter; LVEDD¼ left
ventricular end-diastolic diameter; LVESD¼ left ventricular end-
systolic diameter.
T. Yamaguchi et al. / Journal of Arrhythmia 28 (2012) 175–181176size, and evaluate the left ventricular function. Those having other
risk factors of AF, such as age (465 years), hypertension, diabetes
mellitus, structural heart disease, hyperthyroidism, obesity, and
heavy alcohol intake [9–12], were excluded from this study. AF
was classiﬁed as paroxysmal, persistent, or long-standing accord-
ing to the deﬁnitions of the consensus statement on catheter and
surgical ablation of AF [20].
For 11 of the 22 patients who underwent PVAI to treat AF, AF-
related symptoms reduced their exercise tolerance and limited
their activities in sports.
2.2. Pulmonary vein antrum isolation
After giving informed consent, all 11 patients underwent an
electrophysiological study in a fasting and conscious sedated state.
All antiarrhythmic drugs (AADs) were discontinued for at least 5 half-
lives prior to the study. PVAI was performed using a deﬂectable 7-Fr
quadripolar, non-irrigated 8-mm tip electrode ablation catheter
(Fantasista
TM
; Japan Lifeline Co. Ltd., Tokyo, Japan) under navigation
using EnSite Array
TM
(N¼5) or EnSite NavXTM (N¼7) (St. Jude Medical,
St. Paul, MN, USA). The details of PVAI performed using EnSite Array
TM
or NavX
TM
have been described elsewhere [21–24]. In addition to
PVAI, linear ablation at the tricuspid isthmus was performed in all
patients.
2.3. Follow-up after PVAI
For follow-up examinations after PVAI, patient visits occurred
at the outpatient clinic at 2 weeks, 1 month, and every 1–3
months thereafter. A 12-lead electrocardiogram was recorded at
each visit. Routine 24-hour Holter monitoring was performed
3 months after PVAI and every 6 months thereafter; at least
1 treadmill exercise test was performed 6 months after PVAI.
During 24-hour Holter monitoring, the patients were asked to
perform their usual sports activities to allow detection of atrial
tachyarrhythmia recurrence. Any symptomatic or asymptomatic
atrial tachyarrhythmia was considered recurrence. When a recur-
rence was observed and the patient agreed, a second session was
performed. AADs were continued for at least 3 months and then
tapered off by 6 months.
2.4. Statistical analysis
Continuous variables are expressed as the mean7SD or
number and percentage, as appropriate. Continuous variables
were compared using the Student’s t-test for paired and unpaired
comparison, when appropriate. Categorical variables were com-
pared with a Fisher’s exact test. Results with a p value of o0.05
were considered statistically signiﬁcant.3. Results
3.1. Patient characteristics
The baseline characteristics of the 22 patients are shown in
Table 1. None of the patients had structural heart disease. The
baseline heart rate during sinus rhythm was 5279 beats per
minute (bpm), and the baseline heart rate during AF at rest was
less than 80 bpm in 11 patients (50%) without any rate-control
drugs. Twelve patients had paroxysmal AF. Nine patients had
persistent AF lasting for 41 week (range: 1 week to 12 months),
and 1 patient had long-standing AF for 7 years. Of these 10
patients, 5 had persistent AF at the time of the diagnosis; in the
remaining 5 patients, paroxysmal AF progressed to persistent
(N¼4) or long-standing AF (N¼1) over the course of the study.3.2. Symptoms and medical treatments
All 22 patients had symptoms including palpitation and
decreased exercise tolerance (e.g., earlier manifestation of shortness
of breath than before, easy fatigability, and chest discomfort during
exercise). It was noted that palpitation was less prevalent (N¼8,
36%) and, when present, the magnitude was mostly weak and the
main manifestations were exercise-related. Twelve patients (55%;
4 paroxysmal, 7 persistent, and 1 long-standing AF) had no symp-
toms at rest or during mild exertion, whereas 19 (86%) patients
developed AF-related symptoms during exercise. It should be
emphasized that 14 patients (64%) had exercise-induced AF, which
was revealed by a treadmill exercise test (N¼5) or was suggested by
the sudden onset of symptoms during exercise (N¼9), including
reduced exercise tolerance, shortness of breath, and chest discomfort.
Furthermore, paroxysmal AF occurred at night or after meals in
5 patients; 2 of these patients also had exercise-induced AF.
Fig. 1 shows an example of paroxysmal AF in an endurance
athlete. The patient was a 40-year-old marathon runner, and the
12-lead electrocardiography exhibited repetitive paroxysmal AF
with short durations. He was not treated previously because he
had no symptoms; despite having AF, the patient exhibited a
normal range of heart rate with a relatively regular RR interval.
However, 2 years later, he felt a sudden impairment of exercise
sustainability during running, and he was diagnosed with parox-
ysmal AF. Fig. 2 shows another example of paroxysmal AF that
occurred during a treadmill exercise test in a 53-year-old jogger.
Premature atrial contraction repetitively occurred at 3 min and
30 s after the beginning of exercise and AF eventually developed
at 7 min and 40 s, which was self-terminated after the exercise.
AADs, such as bepridil (N¼9) and pilsicainide (N¼15), were
prescribed in 18 patients (82%), but effectively suppressed AF in only
3 patients with paroxysmal AF (17%) during an observation period of
4.473.2 years. Although AADs were effective in the beginning of
the observation period, they tended to become ineffective over time.
Amiodarone and sotalol were not prescribed to any patients. AADs
were not prescribed to 4 patients (paroxysmal¼2, persistent¼2)
because their symptoms were mild except during exercise. Atrial
ﬂutter (AFL) was documented in 5 patients (23%) under no AAD
(N¼1) or after oral pilsicainide (N¼4), which failed to suppress the
AFL. Beta-blockers were not well tolerated in most patients because
they exacerbated the loss of exercise tolerance.
In one typical case of exercise-induced paroxysmal AF, the
patient’s heart rate during exercise-induced AF became 4250 bpm,
although the sinus rate at rest was o60 bpm. The patient was
prescribed bisoprolol (2.5 mg, once a day) to suppress his exercise-
induced AF. A week later, the AF persisted and the heart rate
Fig. 1. Twelve lead electrocardiograms were recorded from a 40-year-old marathon runner. Atrial premature contractions and AF with short duration were recorded
(arrows). He had no symptoms during rest and exercise at the time, but 2 years later, he experienced symptomatic exercise-induced paroxysmal AF. AF was completely
eliminated by PV antrum isolation.
Fig. 2. Exercise-induced atrial ﬁbrillation (AF) during a standard Bruce protocol in a 53-year-old man. Twelve-lead electrocardiograms at 1:30 min (panel A), 3:30 mins
(panel B), 7:40 mins (panel C), and 8:00 min (panel D) are shown; the left half of each panel shows limb leads and the right half shows precordial leads. At 3:30 min after
the start of exercise, atrial premature contractions were observed (arrows) and AF eventually developed (panel C). At 8:00 min, the patient complained of shortness of
breath and chest discomfort, although he had no symptoms before the AF occurrence.
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orthostatic hypotension and felt constant fatigue, possibly due
to bradycardia. Although transthoracic echocardiography exhibited
normal left ventricular function, the blood concentration of brain
natriuretic peptide (BNP) increased to 307 pg/ml (normal range,
o18 pg/ml). After cessation of bisoprolol, his condition returned
to the previous level and the BNP concentration decreased to
49 pg/ml.
3.3. Pulmonary vein antrum isolation
Eleven out of the 22 patients underwent PVAI (PVAI patients),
but the remaining 11 patients did not agree to the catheter
ablation (non-PVAI patients). All of the PVAI patients complained
of less exercise tolerance. AADs were not effective in any of the
patients. We compared the clinical characteristics between PVAIpatients and non-PVAI patients. There were no signiﬁcant differ-
ences in the clinical characteristics between the 2 groups
(Table 2).
Focal activities, which triggered AF, were observed in the
pulmonary veins in 8 patients (73%). Fig. 3 shows that the antrum
isolation of the left inferior PV under navigation using the EnSite
Array resulted in AF termination in the atrium while localized
AF persisted only in the left inferior PV, suggesting that the
left inferior PV is responsible for maintaining AF. In addition to
PVAI, a linear ablation at the tricuspid isthmus was performed
in all patients. In 10 patients, no other ablative procedures were
performed. In 1 patient with persistent AF lasting for 46 months,
additional left atrial (LA) line creations at the LA roof and septum
were performed following PVAI because AF was not eliminated by
PVAI alone. In all patients, electrical isolation of all 4 PVs was
achieved without any complications.
Table 2
Comparisons of PVAI and non-PVAI patient characteristics.
PVAI patients
N¼11
Non-PVAI patients
N¼11
P
value
Age (years) 4577 4777 0.5486
Type of AF
Paroxysmal 5 (45%) 7 (64%) 0.3870
Persistent 6 (55%) 3 (27%)
Long-standing 0 (0%) 1 (9%)
Duration of AF persistence
(months)a
3.372.8 6.077.1
History of AF (years) 4.472.4 3.873.8 0.8316
LAD (mm) 3974 3977 0.9705
LVEDD (mm) 5375 5374 0.6700
LVESD (mm) 3375 3474 0.6702
LVEF (%) 6779 6876 0.7898
BMI (kg/m2) 23.072.4 24.072.4 0.5474
Sinus rate at rest (bpm) 5376 53711 0.8903
PVAI¼pulmonary vein antrum isolation; AF¼atrial ﬁbrillation; BMI¼body mass
index; bpm¼beats per minute; LAD¼anteroposterior left atrial diameter; LVEDD¼
left ventricular end-diastolic diameter; LVESD¼ left ventricular end-systolic diameter.
a Cases are limited in patients with persistent AF.
Fig. 3. Pulmonary vein antrum isolation (PVAI) and the termination of AF in a 42-year-o
aspect (left) and left aspect (right). The brown tags indicate the ablation lines along the
indicate the point where the electrical isolation of the PV was performed. The PVAI resu
within the LIPV. Panel B shows the electrocardiograms at leads I, aVF, and V1 and the in
(CS proximal to distal). Blue arrows indicate the sinus rhythm in the right atrium and c
to 19–20) exhibited localized AF. AF¼atrial ﬁbrillation, CS¼coronary sinus, HRA¼h
pulmonary vein, LSPV¼ left superior pulmonary vein, MV¼mitral valve, RA¼right atriu
interpretation of the references to color in this ﬁgure legend, the reader is referred to
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After the ﬁrst session, paroxysmal AF recurred in 3 out of 11
patients (27%). One patient, who had persistent AF lasting for 46
months before PVAI, underwent second and third sessions; in
every session, some LA–PV reconnections were observed and PVAI
was repeated until no AF recurrence was detected. The remaining
2 patients, who had AF recurrence, did not undergo additional
sessions because a previously unsuccessful AAD could suppress
the AF after the ﬁrst session, which allowed them to resume their
sports activities.
After the ﬁnal session, 9 patients (82%) had no recurrence of AF
and were not prescribed AADs. The exercise tolerance returned to
the previous level in all patients during the 2179 month follow-up.
In addition, transthoracic echocardiography revealed that the LA
diameter signiﬁcantly decreased from 3974mm to 3572 mm
after the PVAI (p¼0.0224), although the left ventricular diastolic
and systolic diameter and the ejection fraction did not change. The
heart rate during sinus rhythm at rest obtained at the outpatient
clinic signiﬁcantly increased from 5177 bpm before PVAI to
6279 bpm (p¼0.0016) at 1272 months after the PVAI.ld man. The upper panel shows the geometry of the left atrium from the posterior
left ipsilateral PV (LIPV) antrum. The orange tags, just below the LIPV (red arrows),
lted in the termination of AF in the left and right atrium, but localized AF persisted
tracardiac electrograms in the high RA (HRA proximal to distal) and coronary sinus
oronary sinus; electrograms recorded at the circular catheter in the LIPV (LIPV 1–2
igh right atrium, LA¼ left atrium, LAA¼ left atrial appendage, LIPV¼ left inferior
m, RIPV¼right inferior pulmonary vein, RSPV¼right superior pulmonary vein. (For
the web version of this article.)
Fig. 4. Holter electrocardiographic recordings after pulmonary vein antrum isolation (PVAI) in a 54-year-old man. The trendgrams of heart rate at 6 months (Panel A) and
12 months (Panel B) after PVAI are shown. The arrowheads in panels A and B indicate that the heart rate increased during jogging. The arrow in panel B indicates repetitive
sudden increases in the heart rate, which was due to skiing not AF; the heart rate repeatedly increased when skiing down a slope and it decreased when riding the ski lift
up a hill. Panel C shows electrograms at a maximum heart rate of 142 bpm during jogging (the timing of the asterisk in panel B), which shows sinus tachycardia. No atrial
tachyarrhythmia was documented by Holter electrocardiographic recordings, even during exercise. bpm¼beats per minute.
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recordings after PVAI in a 42-year-old male patient with persistent
AF lasting for 46 months. The heart rate trendgrams obtained by
Holter monitoring at 6 months and 12 months after the PVAI
exhibited no AF recurrence during exercise. His exercise tolerance
returned to the previous level during sinus rhythm.
Regarding the clinical course of non-PVAI patients, 1 paroxysmal
AF patient progressed to persistent AF and 1 persistent AF patient
progressed to long-standing AF during the follow-up period of 24
months, despite the use of AADs.4. Discussion
4.1. Main ﬁndings
Most endurance athletes with AF experience decreased exer-
cise tolerance during their endurance sports activities although
half of them have no symptoms during rest or mild exertion.
AADs, including bepridil and sodium channel blockers, are not
effective in the majority of patients. Here, we showed that PVAI
eliminated AF in most patients, suggesting that the mechanism of
AF seems to be linked to focal activities originating from the
pulmonary veins.
4.2. Atrial ﬁbrillation in athletes
Published reports have linked autonomic nerve activity to the
occurrence of AF. In this study, 14 patients (64%) had exercise-
induced AF while 5 patients (23%) had AF episodes at rest or after
meals; the former seems to relate to increased sympathetic nerve
activity and the latter to increased vagal nerve activity. In
endurance athletes, vagal tone seems to be increased at rest
[25], which is suggested by both slow heart rates during sinus
rhythm and slow ventricular rates during AF. Clinical andexperimental data show that increased vagal nerve activity
shortens the atrial refractory period inhomogeneously by
increasing the IkAch current and increases the dispersion of the
atrial refractory period, facilitating reentry [26,27]. In contrast,
increased sympathetic nerve activity is also reported to shorten
the atrial refractory period and increase the dispersion by
increasing the Iks current, which facilitates reentry and late phase
3 early after depolarization by increasing the ICaL and Ca
2þ
release from the sarcoplasmic reticulum [28].
The maintenance of AF requires not only an initiator but also an
AF substrate, including atrial ﬁbrosis, loss of gap junctions, and LA
enlargement [29,30]. Long-term endurance sports cause LA enlarge-
ment. In fact, athletes have a larger atrium compared to sedentary
controls [31,32]. Subsequent increases in the LA wall strain and/or
stretch are reported to relate to AF maintenance [25]. In this study,
mean LA dimension was 3976 mm (range, 3249 mm), which
seems higher than control subjects of similar age and the same sex.
Furthermore, it is reported that athletes show higher levels of
collagen markers, including plasma PICP, CITP, and TIMP-1, when
compared with sedentary controls [33]. Therefore, endurance ath-
letes seem to be prone to AF. The European Society of Cardiology
(ESC) guidelines for the management of patients with AF reported
that people who perform endurance sports, especially competitive
sports, are likely to develop AF [34].4.3. Pharmacological treatment
The easiest and least expensive therapy for AF in endurance
athletes would be to stop exercising [34], which is always very
difﬁcult. The ESC guidelines for the management of patients with AF
report that competitive athletes are difﬁcult to manage because
many of the treatment options are not allowed and the recommen-
dation to reduce exercise is not easily accepted. In our experience,
the patients usually refused to cease or reduce their exercise
T. Yamaguchi et al. / Journal of Arrhythmia 28 (2012) 175–181180because sports play an important role in their lives and they are
passionate about sports activities.
Although class 1C agents, such as ﬂecainide or propafenone, are
recommended in general [25,34], AADs were usually ineffective in
the majority of the patients in this study. In many cases, the drugs
were effective at the beginning of treatment, but became gradually
ineffective with time. Furthermore, oral administration of sodium
channel blockers led to AFL in some patients, which aggravated their
symptoms and worsened their quality of life. In extreme situations,
the atrial rate of AFL is decreased by AADs; thus, one-to-one
atrioventricular conduction may occur during exercise. In contrast,
the use of beta-blockers to control rate during AF is usually not
acceptable because the exercise intolerance is exacerbated due to
inappropriate heart rate response and negative inotropic effects.
Further, beta-blockers worsen their bradycardia at rest, which
sometimes causes dizziness and general fatigue or even heart failure
due to the combination of negative inotropic effects and extreme
bradycardia.4.4. Catheter ablation for AF
We performed PVAI in 11 patients with drug refractory AF.
No recurrence was noted after PVAI without AAD in 9 patients,
but 1 patient required 3 sessions to eliminate AF. In the other
2 patients, an AAD suppressed AF after a single PVAI. All patients
felt that their exercise tolerance returned to previous levels after
the PVAI. Therefore, PVAI should be a preferable treatment option,
especially for athletes with paroxysmal AF or early-stage persis-
tent AF, as long as the patients have signiﬁcant symptoms and
wish to continue their sports activities without impairment of
exercise tolerance.
However, for athletes with AF, there are important differ-
ences to consider prior to performing PVAI. First, the atrial wall
of endurance athletes may be thicker than that of sedentary
patients. We have observed that it is sometimes challenging to
make a transmural lesion by radiofrequency energy delivery at
the PV antrum in endurance athletes compared with sedentary
patients. Second, recurrences are often observed after a single
session [18,19] and repeated procedures would be required.
Third, they receive catheter ablations to resume endurance
sports at full intensity. Attention should be paid to avoid
complications such as PV stenosis and phrenic nerve injury,
because these complications may lead to impairment of exercise
tolerance even if their magnitude is mild.4.5. Limitations
The main limitation of this study is the small size of the study
population. Therefore, the indications for PVAI should be con-
sidered carefully. However, PVAI should be effective to control AF
in endurance athletes. In addition, we evaluated the exercise
tolerance only on the basis of subjective symptoms. However,
objective evaluations, such as cardiopulmonary exercise testing,
could be performed to accurately evaluate the exercise tolerance.5. Conclusion
AF is asymptomatic at rest in about half of the patients, but
it manifests as less exercise tolerance in the majority of
patients. It is frequently induced by exercise and usually drug
refractory. AF originates from the PVs and PVAI could be an
effective therapy for AF in athletic patients as well as non-
athletic patients.Conﬂict of interest
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